HCV Immunogenic Composition With Conserved T-Cell Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compositions and methods to induce immune responses to hepatitis C virus (HCV) that are effective across multiple genotypes and can elicit broad-spectrum T-cell responses in the human population.
Innovation Solution
An immunogenic composition comprising HCV E1/E2 heterodimeric polypeptides and heterologous polypeptides containing conserved T-cell epitopes presented through multiple HLA alleles, combined with a pharmaceutically acceptable excipient, to induce robust immune responses against HCV.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If HCV E1/E2 heterodimeric polypeptides alone are used as vaccine antigen, then the antigen structure is simple and easy to produce, but the immune response is insufficient and genotype coverage is limited
Solution Approach 1:
The patent combines HCV E1/E2 heterodimeric polypeptides with heterologous polypeptides containing conserved T-cell epitopes from other HCV proteins (such as core, NS3, NS4, NS5 proteins) to create a composite vaccine composition. This composite approach broadens the immune response to cover multiple HCV genotypes while maintaining ease of production through recombinant expression systems.
Solution Approach 2:
The patent merges B-cell epitopes (from E1/E2 heterodimers that induce neutralizing antibodies) with T-cell epitopes (from heterologous polypeptides that stimulate cellular immunity) into a single vaccine composition. This combination synergistically enhances both humoral and cellular immune responses, overcoming the limitations of using E1/E2 alone.
2Ease of manufacture
If vaccine is designed for single HCV genotype, then the antigen specificity is high and production is simplified, but the cross-protection against other genotypes is insufficient
Solution Approach 1:
The patent incorporates heterologous polypeptides containing T-cell epitopes that are conserved across multiple HCV genotypes. These epitopes are selected from highly conserved regions of HCV proteins (such as core, NS3, NS4, NS5) that show minimal variation between genotypes, enabling the vaccine to elicit T-cell responses that recognize and protect against diverse HCV strains.
Solution Approach 2:
The vaccine composition combines genotype-specific E1/E2 heterodimers with genotype-transcendent heterologous polypeptides containing conserved T-cell epitopes. This composite structure maintains the advantages of genotype-specific antigen presentation while adding broad-spectrum T-cell immunity that provides cross-protection against multiple HCV genotypes.
3Device complexity
If only E1 and E2 polypeptides are included in the composition, then the composition is simple and cost-effective, but the T-cell response is inadequate for broad protection
Solution Approach 1:
The patent extracts conserved T-cell epitopes from various HCV proteins (core, NS3, NS4, NS5) and incorporates them into heterologous polypeptides that are distinct from the E1/E2 heterodimeric structure. This extraction approach allows the vaccine to capture essential T-cell epitopes without including entire complex viral proteins, maintaining composition simplicity while enhancing T-cell response.
Solution Approach 2:
The vaccine creates a composite composition where E1/E2 heterodimers (providing B-cell epitopes) are combined with heterologous polypeptides (providing T-cell epitopes). This composite structure achieves robust dual immunity with controlled complexity, as the heterologous polypeptides are designed to contain only the essential conserved epitopic regions rather than full-length viral proteins.
Data Source
AI summary
The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.